サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1618995

成長因子の世界市場：産業分析・規模・シェア・成長・動向・予測 (2024-2031年)

Growth Factors Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031

出版日
ページ情報
英文 194 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
成長因子の世界市場：産業分析・規模・シェア・成長・動向・予測 (2024-2031年)
出版日: 2024年12月19日
発行: Persistence Market Research
ページ情報: 英文 194 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

主な洞察

  • 成長因子の市場規模 (2024年)：22億米ドル
  • 市場規模の予測 (2031年)：33億米ドル
  • 世界の市場成長率 (2024～2031年)：CAGR 5.8%

市場促進要因：

成長因子の市場は主に、癌や糖尿病などの慢性疾患の有病率の上昇によって牽引されており、高度な治療ソリューションが必要とされています。成長因子は標的療法や再生医療において極めて重要な役割を果たし、組織工学や創傷治癒の応用における採用をさらに促進しています。バイオテクノロジーにおける技術の進歩は、組換え成長因子の生産に革命をもたらし、その入手しやすさと有効性を高めています。さらに、世界の高齢化により、革新的な治療アプローチに対する需要が急増しています。また、個別化医療の進歩が精密治療における成長因子の可能性を高めています。

市場抑制要因：

良好な成長見通しにもかかわらず、世界の成長因子市場はいくつかの課題に直面しています。組換え成長因子の生産と商業化に伴う高コストは、特にコストに敏感な市場において、その普及を妨げる可能性があります。規制上のハードルや厳しい承認プロセスは、製品の上市を遅らせ、市場の成長に影響を与える可能性があります。さらに、新興国市場では成長因子の治療応用に関する認知度が低く、代替治療法との競合が市場にとってさらなる課題となります。

市場機会：

再生医療や慢性疾患管理における成長因子の新規用途開発には大きな成長機会が存在します。腫瘍や個別化医療などの新興分野への成長因子の拡大は、技術革新の新たな道を開くものです。バイオテクノロジー企業、調査機関、ヘルスケアプロバイダー間の協力的な取り組みにより、この領域での進歩が加速されると予想されます。さらに、精密医療の導入が進むことで、特に医療インフラが発達した先進地域では、大きな市場開拓の可能性があります。医療投資の拡大に支えられた新興国の未開拓市場は、市場にとってもう一つの有望な成長分野です。

当レポートでは、世界の成長因子の市場を調査し、市場の定義と概要、市場促進要因・抑制要因、各種動向、市場機会、課題、市場規模 (金額・一部数量) の推移・予測、各種区分・地域/主要国別の詳細分析、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 推進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • マクロ経済要因
  • COVID-19の影響分析
  • 予測要因：関連性と影響

第3章 付加価値の洞察

  • 規制状況
  • 製品採用分析
  • バリューチェーン分析
  • 主要な取引と合併
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の成長因子市場の展望：推移と予測

  • 主なハイライト
    • 市場規模・前年比成長率
    • 収益機会
  • 市場規模の分析・予測
  • 世界市場の展望：製品別
  • 世界市場の展望：グレード別
  • 世界市場の展望：用途別
  • 世界市場の展望：発現ホストシステム別
  • 世界市場の展望：作用機序別
  • 世界市場の展望：由来種別
  • 世界市場の展望：エンドユーザー別

第5章 世界の成長因子市場の展望：地域別

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の予測
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場の魅力分析：地域

第6章 北米の成長因子市場の展望：推移と予測

  • 主なハイライト
  • 市場規模の推移
    • 国別
    • 製品別
    • グレード別
    • 用途別
    • 発現ホストシステム別
    • 作用機序別
    • 由来種別
    • エンドユーザー別
  • 市場規模の推移・予測：国別
    • 米国
    • カナダ
  • 市場規模の推移・予測：製品別
    • トランスフォーミング成長因子 (TGF)
    • 表皮成長因子 (EGF)
    • 血小板由来成長因子 (PDGF)
    • 線維芽細胞増殖因子 (FGF)
    • インスリン様成長因子 (IGF)
    • 血管内皮増殖因子 (VEGF)
    • 肝細胞増殖因子 (HGF)
    • 腫瘍壊死因子 (TNF)
    • インターロイキン
    • その他
  • 市場規模の推移・予測：グレード別
    • GMPグレード
    • 非GMPグレード
  • 市場規模の推移・予測：用途別
    • 腫瘍
    • 血液
    • 傷の治癒
    • 皮膚科
    • 心臓血管疾患・糖尿病
    • 細胞治療・体外製造
    • その他
  • 市場規模の推移・予測：発現ホストシステム別
    • 動物由来成長因子
    • 組み換え成長因子
  • 市場規模の推移・予測：作用機序別
    • 血管新生成長因子
    • 抗アポトーシス成長因子
    • 分裂促進成長因子
  • 市場規模の推移・予測：由来種別
    • ヒト
    • ブタ
    • マウス
    • ラット
    • その他
  • 市場規模の推移・予測：エンドユーザー別
    • 製薬・バイオテクノロジー企業
    • 研究センター・学術機関
    • CRO
  • 市場の魅力分析

第7章 欧州の成長因子市場の展望：推移と予測

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の推移・予測：国別
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • トルコ
    • その他
  • 市場規模の推移・予測：製品別
  • 市場規模の推移・予測：グレード別
  • 市場規模の推移・予測：用途別
  • 市場規模の推移・予測：発現ホストシステム別
  • 市場規模の推移・予測：作用機序別
  • 市場規模の推移・予測：由来種別
  • 市場規模の推移・予測：エンドユーザー別
  • 市場の魅力分析

第8章 東アジアの成長因子市場の展望：推移と予測

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の推移・予測：国別
    • 中国
    • 日本
    • 韓国
  • 市場規模の推移・予測：製品別
  • 市場規模の推移・予測：グレード別
  • 市場規模の推移・予測：用途別
  • 市場規模の推移・予測：発現ホストシステム別
  • 市場規模の推移・予測：作用機序別
  • 市場規模の推移・予測：由来種別
  • 市場規模の推移・予測：エンドユーザー別
  • 市場の魅力分析

第9章 南アジア・オセアニアの成長因子市場の展望：推移と予測

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の推移・予測：国別
    • インド
    • 東南アジア
    • オーストラリア
    • その他
  • 市場規模の推移・予測：製品別
  • 市場規模の推移・予測：グレード別
  • 市場規模の推移・予測：用途別
  • 市場規模の推移・予測：発現ホストシステム別
  • 市場規模の推移・予測：作用機序別
  • 市場規模の推移・予測：由来種別
  • 市場規模の推移・予測：エンドユーザー別
  • 市場の魅力分析

第10章 ラテンアメリカの成長因子市場の展望：推移と予測

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の推移・予測：国別
    • ブラジル
    • メキシコ
    • その他
  • 市場規模の推移・予測：製品別
  • 市場規模の推移・予測：グレード別
  • 市場規模の推移・予測：用途別
  • 市場規模の推移・予測：発現ホストシステム別
  • 市場規模の推移・予測：作用機序別
  • 市場規模の推移・予測：由来種別
  • 市場規模の推移・予測：エンドユーザー別
  • 市場の魅力分析

第11章 中東・アフリカの成長因子市場の展望：推移と予測

  • 主なハイライト
  • 市場規模の推移
  • 市場規模の推移・予測：国別
    • GCC諸国
    • エジプト
    • 南アフリカ
    • 北アフリカ
    • その他
  • 市場規模の推移・予測：製品別
  • 市場規模の推移・予測：グレード別
  • 市場規模の推移・予測：用途別
  • 市場規模の推移・予測：発現ホストシステム別
  • 市場規模の推移・予測：作用機序別
  • 市場規模の推移・予測：由来種別
  • 市場規模の推移・予測：エンドユーザー別
  • 市場の魅力分析

第12章 競合情勢

  • 市場シェア分析
  • 市場構造
  • 企業プロファイル (詳細- 概要、財務、戦略、最近の動向)
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • Lonza Group AG
    • F. Hoffmann-La Roche Ltd.
    • Sartorius CellGenix GmbH
    • Bio-Techne Corporation
    • GenScript
    • Miltenyi Biotec.
    • Abcam PLC
    • Sino Biological Inc.
    • Cell Signaling Technology, Inc.
    • ACROBiosystems
    • Becton, Dickinson, and Company
    • Creative Bioarray
    • Applied Biological Materials (abm) Inc.
    • GE Healthcare
    • Meridian Bioscience Inc.
    • Repligen Corporation
    • Aviva Systems Biology Corporation (GenWay Biotech)
    • Leadgene Biomedical, Inc.
    • Boster Bio
    • Prospec-Tany Technogene Ltd.
    • Proteintech Group, Inc.
    • AJINOMOTO CO.,INC
    • STEMCELL Technologies
    • Akron Biotech
    • PeproTech Inc.

第13章 付録

目次
Product Code: PMRREP4456

Persistence Market Research has recently released a comprehensive report on the global Growth Factors Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions

Key Insights:

  • Growth Factors Market Size (2024E): US$ 2.2 Bn
  • Projected Market Value (2031F): US$ 3.3 Bn
  • Global Market Growth Rate (CAGR 2024 to 2031): 5.8%

Growth Factors Market - Report Scope:

The global growth factors market comprises biologically active proteins or peptides that play essential roles in cell proliferation, differentiation, and tissue regeneration. These compounds are increasingly being used in regenerative medicine, oncology, and chronic disease management. The market's growth trajectory is influenced by innovations in biotechnology, enabling the production of recombinant growth factors with enhanced efficacy and scalability. The market also benefits from supportive government initiatives, rising investments in biomedical research, and the increasing prevalence of chronic diseases worldwide.

Market Drivers:

The growth factors market is primarily driven by the rising prevalence of chronic diseases such as cancer and diabetes, necessitating advanced therapeutic solutions. Growth factors play a pivotal role in targeted therapies and regenerative medicine, further driving their adoption in tissue engineering and wound healing applications. Technological advancements in biotechnology have revolutionized the production of recombinant growth factors, enhancing their accessibility and effectiveness. Additionally, the global aging population is creating a surge in demand for innovative therapeutic approaches. Government initiatives and increased funding for biomedical research provide further impetus to the market, while advancements in personalized medicine amplify the potential of growth factors in precision therapies.

Market Restraints:

Despite the favorable growth prospects, the global growth factors market faces several challenges. The high costs associated with the production and commercialization of recombinant growth factors can hinder their widespread adoption, particularly in cost-sensitive markets. Regulatory hurdles and stringent approval processes can delay product launches, impacting market growth. Furthermore, limited awareness about the therapeutic applications of growth factors in developing regions and competition from alternative treatment modalities pose additional challenges for the market.

Market Opportunities:

Significant growth opportunities exist in the development of novel applications for growth factors in regenerative medicine and chronic disease management. The expansion of growth factors into emerging fields such as oncology and personalized medicine opens up new avenues for innovation. Collaborative efforts between biotechnology firms, research institutions, and healthcare providers are expected to accelerate advancements in this domain. Moreover, the increasing adoption of precision medicine presents substantial market potential, particularly in developed regions with advanced healthcare infrastructure. Untapped markets in emerging economies, supported by growing healthcare investments, represent another promising growth area for the market.

Key Questions Answered in the Report:

  • What are the primary factors driving the global growth of the growth factors market?
  • Which therapeutic areas are gaining the highest adoption across different regions?
  • How are advancements in biotechnology shaping the competitive landscape of the growth factors market?
  • Who are the key players in the growth factors market, and what strategies are they employing to maintain their market positions?
  • What are the emerging trends and future outlooks for the global growth factors market?

Competitive Intelligence and Business Strategy:

Leading companies in the global growth factors market, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, and Lonza Group AG, are focusing on innovations in biotechnology to maintain their competitive edge. These players are leveraging advancements in recombinant technology to develop highly efficacious growth factors for targeted therapies and regenerative applications. Partnerships between pharmaceutical companies and academic research institutions are driving research and accelerating commercialization timelines. Companies are also emphasizing affordability and accessibility to cater to a broader patient population while aligning with global healthcare goals.

Key Companies Profiled:

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Lonza Group AG
  • F. Hoffmann-La Roche Ltd.
  • Sartorius CellGenix GmbH
  • Bio-Techne Corporation
  • GenScript
  • Miltenyi Biotec.
  • Abcam PLC
  • Sino Biological Inc.
  • Cell Signaling Technology, Inc.
  • ACROBiosystems
  • Becton, Dickinson, and Company
  • Creative Bioarray
  • Applied Biological Materials (abm) Inc.
  • GE Healthcare
  • Meridian Bioscience Inc.
  • Repligen Corporation
  • Aviva Systems Biology Corporation (GenWay Biotech)
  • Leadgene Biomedical, Inc.
  • Boster Bio
  • Prospec-Tany Technogene Ltd.
  • Proteintech Group, Inc.
  • AJINOMOTO CO., Inc.
  • STEMCELL Technologies
  • Akron Biotech
  • PeproTech Inc.

Growth Factors Market Segmentation:

By Product

  • Transforming Growth Factors (TGF)
  • Epidermal Growth Factors (EGFs)
  • Platelet-derived Growth Factors (PDGFs)
  • Fibroblast Growth Factors (FGFs)
  • Insulin-like Growth Factors (IGFs)
  • Vascular Endothelial Growth Factors (VEGFs)
  • Hepatocyte Growth Factors (HGFs)
  • Tumor Necrosis Factors (TNFs)
  • Interleukins
  • Others

By Grade

  • GMP Grade
  • NON-GMP Grade

By Application

  • Oncology
  • Hematology
  • Wound Healing
  • Dermatology
  • Cardiovascular Disease and Diabetes
  • Cell Therapy and EX-vivo Manufacturing
  • Others

By Expression Host System

  • Animal-derived
  • Recombinant

By Mode of Action

  • Angiogenic
  • Anti-apoptotic
  • Mitogenic

By Species Origin

  • Human
  • Pig
  • Mouse
  • Rat
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Research Centers and Academic Institutes
  • Contract Research Organizations

By Region

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Growth Factors Market Snapshot, 2024 and 2031
  • 1.2. Market Opportunity Assessment, 2024 - 2031, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
    • 2.3.3. Global Healthcare Spending Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Regulatory Landscape
  • 3.2. Product Adoption Analysis
  • 3.3. Value Chain Analysis
  • 3.4. Key Deals and Mergers
  • 3.5. PESTLE Analysis
  • 3.6. Porter's Five Force Analysis

4. Global Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019 - 2023
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2024 - 2031
  • 4.3. Global Growth Factors Market Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019 - 2023
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
      • 4.3.3.1. Transforming Growth Factors (TGF)
        • 4.3.3.1.1. Activin
        • 4.3.3.1.2. Bone Morphogenetic Proteins (BMPs)
        • 4.3.3.1.3. TGF-beta Proteins
      • 4.3.3.2. Epidermal Growth Factors (EGFs)
      • 4.3.3.3. Platelet-Derived Growth Factors (PDGFs)
      • 4.3.3.4. Fibroblast Growth Factors (FGFs)
      • 4.3.3.5. Insulin-like Growth Factors (IGFs)
      • 4.3.3.6. Vascular Endothelial Growth Factors (VEGFs)
      • 4.3.3.7. Hepatocyte Growth Factors (HGFs)
      • 4.3.3.8. Tumor Necrosis Factors (TNFs)
      • 4.3.3.9. Interleukins
      • 4.3.3.10. Others
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Growth Factors Market Outlook: Grade
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn) Analysis, By Grade, 2019 - 2023
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
      • 4.4.3.1. GMP Grade
      • 4.4.3.2. NON-GMP Grade
    • 4.4.4. Market Attractiveness Analysis: Grade
  • 4.5. Global Growth Factors Market Outlook: Application
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn) Analysis, By Application, 2019 - 2023
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
      • 4.5.3.1. Oncology
      • 4.5.3.2. Hematology
      • 4.5.3.3. Wound Healing
      • 4.5.3.4. Dermatology
      • 4.5.3.5. Cardiovascular Disease & Diabetes
      • 4.5.3.6. Cell Therapy & EX-vivo Manufacturing
      • 4.5.3.7. Others
    • 4.5.4. Market Attractiveness Analysis: Application
  • 4.6. Global Growth Factors Market Outlook: Expression Host System
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Bn) Analysis, By Expression Host System, 2019 - 2023
    • 4.6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
      • 4.6.3.1. Animal Derived
      • 4.6.3.2. Recombinant
    • 4.6.4. Market Attractiveness Analysis: Expression Host System
  • 4.7. Global Growth Factors Market Outlook: Mode of Action
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Bn) Analysis, By Mode of Action, 2019 - 2023
    • 4.7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
      • 4.7.3.1. Angiogenic
      • 4.7.3.2. Anti-apoptotic
      • 4.7.3.3. Mitogenic
    • 4.7.4. Market Attractiveness Analysis: Mode of Action
  • 4.8. Global Growth Factors Market Outlook: Species Origin
    • 4.8.1. Introduction / Key Findings
    • 4.8.2. Historical Market Size (US$ Bn) Analysis, By Species Origin, 2019 - 2023
    • 4.8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
      • 4.8.3.1. Human
      • 4.8.3.2. Pig
      • 4.8.3.3. Mouse
      • 4.8.3.4. Rat
      • 4.8.3.5. Others
    • 4.8.4. Market Attractiveness Analysis: Species Origin
  • 4.9. Global Growth Factors Market Outlook: End User
    • 4.9.1. Introduction / Key Findings
    • 4.9.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019 - 2023
    • 4.9.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
      • 4.9.3.1. Pharmaceutical and Biotechnology Companies
      • 4.9.3.2. Research Centers & Academic Institutes
      • 4.9.3.3. Contract Research Organizations
    • 4.9.4. Market Attractiveness Analysis: End User

5. Global Growth Factors Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2023
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2023 - 2031
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Grade
    • 6.2.4. By Application
    • 6.2.5. By Expression Host System
    • 6.2.6. By Mode of Action
    • 6.2.7. By Species Origin
    • 6.2.8. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 6.4.1. Transforming Growth Factors (TGF)
      • 6.4.1.1. Activin
      • 6.4.1.2. Bone Morphogenetic Proteins (BMPs)
      • 6.4.1.3. TGF-beta Proteins
    • 6.4.2. Epidermal Growth Factors (EGFs)
    • 6.4.3. Platelet-Derived Growth Factors (PDGFs)
    • 6.4.4. Fibroblast Growth Factors (FGFs)
    • 6.4.5. Insulin-like Growth Factors (IGFs)
    • 6.4.6. Vascular Endothelial Growth Factors (VEGFs)
    • 6.4.7. Hepatocyte Growth Factors (HGFs)
    • 6.4.8. Tumor Necrosis Factors (TNFs)
    • 6.4.9. Interleukins
    • 6.4.10. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 6.5.1. GMP Grade
    • 6.5.2. NON-GMP Grade
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 6.6.1. Oncology
    • 6.6.2. Hematology
    • 6.6.3. Wound Healing
    • 6.6.4. Dermatology
    • 6.6.5. Cardiovascular Disease & Diabetes
    • 6.6.6. Cell Therapy & EX-vivo Manufacturing
    • 6.6.7. Others
  • 6.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 6.7.1. Animal-Derived Growth Factors
    • 6.7.2. Recombinant Growth Factors
  • 6.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 6.8.1. Angiogenic Growth Factors
    • 6.8.2. Anti-Apoptotic Growth Factors
    • 6.8.3. Mitogenic Growth Factors
  • 6.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 6.9.1. Human
    • 6.9.2. Pig
    • 6.9.3. Mouse
    • 6.9.4. Rat
    • 6.9.5. Others
  • 6.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 6.10.1. Pharmaceutical and Biotechnology Companies
    • 6.10.2. Research Centers & Academic Institutes
    • 6.10.3. Contract Research Organizations
  • 6.11. Market Attractiveness Analysis

7. Europe Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Grade
    • 7.2.4. By Application
    • 7.2.5. By Expression Host System
    • 7.2.6. By Mode of Action
    • 7.2.7. By Species Origin
    • 7.2.8. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 7.4.1. Transforming Growth Factors (TGF)
      • 7.4.1.1. Activin
      • 7.4.1.2. Bone Morphogenetic Proteins (BMPs)
      • 7.4.1.3. TGF-beta Proteins
    • 7.4.2. Epidermal Growth Factors (EGFs)
    • 7.4.3. Platelet-Derived Growth Factors (PDGFs)
    • 7.4.4. Fibroblast Growth Factors (FGFs)
    • 7.4.5. Insulin-like Growth Factors (IGFs)
    • 7.4.6. Vascular Endothelial Growth Factors (VEGFs)
    • 7.4.7. Hepatocyte Growth Factors (HGFs)
    • 7.4.8. Tumor Necrosis Factors (TNFs)
    • 7.4.9. Interleukins
    • 7.4.10. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 7.5.1. GMP Grade
    • 7.5.2. NON-GMP Grade
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 7.6.1. Oncology
    • 7.6.2. Hematology
    • 7.6.3. Wound Healing
    • 7.6.4. Dermatology
    • 7.6.5. Cardiovascular Disease & Diabetes
    • 7.6.6. Cell Therapy & EX-vivo Manufacturing
    • 7.6.7. Others
  • 7.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 7.7.1. Animal-Derived Growth Factors
    • 7.7.2. Recombinant Growth Factors
  • 7.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 7.8.1. Angiogenic Growth Factors
    • 7.8.2. Anti-Apoptotic Growth Factors
    • 7.8.3. Mitogenic Growth Factors
  • 7.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 7.9.1. Human
    • 7.9.2. Pig
    • 7.9.3. Mouse
    • 7.9.4. Rat
    • 7.9.5. Others
  • 7.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 7.10.1. Pharmaceutical and Biotechnology Companies
    • 7.10.2. Research Centers & Academic Institutes
    • 7.10.3. Contract Research Organizations
  • 7.11. Market Attractiveness Analysis

8. East Asia Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Grade
    • 8.2.4. By Application
    • 8.2.5. By Expression Host System
    • 8.2.6. By Mode of Action
    • 8.2.7. By Species Origin
    • 8.2.8. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 8.4.1. Transforming Growth Factors (TGF)
      • 8.4.1.1. Activin
      • 8.4.1.2. Bone Morphogenetic Proteins (BMPs)
      • 8.4.1.3. TGF-beta Proteins
    • 8.4.2. Epidermal Growth Factors (EGFs)
    • 8.4.3. Platelet-Derived Growth Factors (PDGFs)
    • 8.4.4. Fibroblast Growth Factors (FGFs)
    • 8.4.5. Insulin-like Growth Factors (IGFs)
    • 8.4.6. Vascular Endothelial Growth Factors (VEGFs)
    • 8.4.7. Hepatocyte Growth Factors (HGFs)
    • 8.4.8. Tumor Necrosis Factors (TNFs)
    • 8.4.9. Interleukins
    • 8.4.10. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 8.5.1. GMP Grade
    • 8.5.2. NON-GMP Grade
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 8.6.1. Oncology
    • 8.6.2. Hematology
    • 8.6.3. Wound Healing
    • 8.6.4. Dermatology
    • 8.6.5. Cardiovascular Disease & Diabetes
    • 8.6.6. Cell Therapy & EX-vivo Manufacturing
    • 8.6.7. Others
  • 8.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 8.7.1. Animal-Derived Growth Factors
    • 8.7.2. Recombinant Growth Factors
  • 8.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 8.8.1. Angiogenic Growth Factors
    • 8.8.2. Anti-Apoptotic Growth Factors
    • 8.8.3. Mitogenic Growth Factors
  • 8.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 8.9.1. Human
    • 8.9.2. Pig
    • 8.9.3. Mouse
    • 8.9.4. Rat
    • 8.9.5. Others
  • 8.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 8.10.1. Pharmaceutical and Biotechnology Companies
    • 8.10.2. Research Centers & Academic Institutes
    • 8.10.3. Contract Research Organizations
  • 8.11. Market Attractiveness Analysis

9. South Asia & Oceania Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Grade
    • 9.2.4. By Application
    • 9.2.5. By Expression Host System
    • 9.2.6. By Mode of Action
    • 9.2.7. By Species Origin
    • 9.2.8. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 9.4.1. Transforming Growth Factors (TGF)
      • 9.4.1.1. Activin
      • 9.4.1.2. Bone Morphogenetic Proteins (BMPs)
      • 9.4.1.3. TGF-beta Proteins
    • 9.4.2. Epidermal Growth Factors (EGFs)
    • 9.4.3. Platelet-Derived Growth Factors (PDGFs)
    • 9.4.4. Fibroblast Growth Factors (FGFs)
    • 9.4.5. Insulin-like Growth Factors (IGFs)
    • 9.4.6. Vascular Endothelial Growth Factors (VEGFs)
    • 9.4.7. Hepatocyte Growth Factors (HGFs)
    • 9.4.8. Tumor Necrosis Factors (TNFs)
    • 9.4.9. Interleukins
    • 9.4.10. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 9.5.1. GMP Grade
    • 9.5.2. NON-GMP Grade
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 9.6.1. Oncology
    • 9.6.2. Hematology
    • 9.6.3. Wound Healing
    • 9.6.4. Dermatology
    • 9.6.5. Cardiovascular Disease & Diabetes
    • 9.6.6. Cell Therapy & EX-vivo Manufacturing
    • 9.6.7. Others
  • 9.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 9.7.1. Animal-Derived Growth Factors
    • 9.7.2. Recombinant Growth Factors
  • 9.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 9.8.1. Angiogenic Growth Factors
    • 9.8.2. Anti-Apoptotic Growth Factors
    • 9.8.3. Mitogenic Growth Factors
  • 9.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 9.9.1. Human
    • 9.9.2. Pig
    • 9.9.3. Mouse
    • 9.9.4. Rat
    • 9.9.5. Others
  • 9.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 9.10.1. Pharmaceutical and Biotechnology Companies
    • 9.10.2. Research Centers & Academic Institutes
    • 9.10.3. Contract Research Organizations
  • 9.11. Market Attractiveness Analysis

10. Latin America Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Grade
    • 10.2.4. By Application
    • 10.2.5. By Expression Host System
    • 10.2.6. By Mode of Action
    • 10.2.7. By Species Origin
    • 10.2.8. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 10.4.1. Transforming Growth Factors (TGF)
      • 10.4.1.1. Activin
      • 10.4.1.2. Bone Morphogenetic Proteins (BMPs)
      • 10.4.1.3. TGF-beta Proteins
    • 10.4.2. Epidermal Growth Factors (EGFs)
    • 10.4.3. Platelet-Derived Growth Factors (PDGFs)
    • 10.4.4. Fibroblast Growth Factors (FGFs)
    • 10.4.5. Insulin-like Growth Factors (IGFs)
    • 10.4.6. Vascular Endothelial Growth Factors (VEGFs)
    • 10.4.7. Hepatocyte Growth Factors (HGFs)
    • 10.4.8. Tumor Necrosis Factors (TNFs)
    • 10.4.9. Interleukins
    • 10.4.10. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 10.5.1. GMP Grade
    • 10.5.2. NON-GMP Grade
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 10.6.1. Oncology
    • 10.6.2. Hematology
    • 10.6.3. Wound Healing
    • 10.6.4. Dermatology
    • 10.6.5. Cardiovascular Disease & Diabetes
    • 10.6.6. Cell Therapy & EX-vivo Manufacturing
    • 10.6.7. Others
  • 10.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 10.7.1. Animal-Derived Growth Factors
    • 10.7.2. Recombinant Growth Factors
  • 10.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 10.8.1. Angiogenic Growth Factors
    • 10.8.2. Anti-Apoptotic Growth Factors
    • 10.8.3. Mitogenic Growth Factors
  • 10.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 10.9.1. Human
    • 10.9.2. Pig
    • 10.9.3. Mouse
    • 10.9.4. Rat
    • 10.9.5. Others
  • 10.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 10.10.1. Pharmaceutical and Biotechnology Companies
    • 10.10.2. Research Centers & Academic Institutes
    • 10.10.3. Contract Research Organizations
  • 10.11. Market Attractiveness Analysis

11. Middle East & Africa Growth Factors Market Outlook: Historical (2019 - 2023) and Forecast (2024 - 2031)

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2023
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Grade
    • 11.2.4. By Application
    • 11.2.5. By Expression Host System
    • 11.2.6. By Mode of Action
    • 11.2.7. By Species Origin
    • 11.2.8. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2023 - 2031
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Product, 2023 - 2031
    • 11.4.1. Transforming Growth Factors (TGF)
      • 11.4.1.1. Activin
      • 11.4.1.2. Bone Morphogenetic Proteins (BMPs)
      • 11.4.1.3. TGF-beta Proteins
    • 11.4.2. Epidermal Growth Factors (EGFs)
    • 11.4.3. Platelet-Derived Growth Factors (PDGFs)
    • 11.4.4. Fibroblast Growth Factors (FGFs)
    • 11.4.5. Insulin-like Growth Factors (IGFs)
    • 11.4.6. Vascular Endothelial Growth Factors (VEGFs)
    • 11.4.7. Hepatocyte Growth Factors (HGFs)
    • 11.4.8. Tumor Necrosis Factors (TNFs)
    • 11.4.9. Interleukins
    • 11.4.10. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Grade, 2023 - 2031
    • 11.5.1. GMP Grade
    • 11.5.2. NON-GMP Grade
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2023 - 2031
    • 11.6.1. Oncology
    • 11.6.2. Hematology
    • 11.6.3. Wound Healing
    • 11.6.4. Dermatology
    • 11.6.5. Cardiovascular Disease & Diabetes
    • 11.6.6. Cell Therapy & EX-vivo Manufacturing
    • 11.6.7. Others
  • 11.7. Current Market Size (US$ Bn) Analysis and Forecast, By Expression Host System, 2023 - 2031
    • 11.7.1. Animal-Derived Growth Factors
    • 11.7.2. Recombinant Growth Factors
  • 11.8. Current Market Size (US$ Bn) Analysis and Forecast, By Mode of Action, 2023 - 2031
    • 11.8.1. Angiogenic Growth Factors
    • 11.8.2. Anti-Apoptotic Growth Factors
    • 11.8.3. Mitogenic Growth Factors
  • 11.9. Current Market Size (US$ Bn) Analysis and Forecast, By Species Origin, 2023 - 2031
    • 11.9.1. Human
    • 11.9.2. Pig
    • 11.9.3. Mouse
    • 11.9.4. Rat
    • 11.9.5. Others
  • 11.10. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2023 - 2031
    • 11.10.1. Pharmaceutical and Biotechnology Companies
    • 11.10.2. Research Centers & Academic Institutes
    • 11.10.3. Contract Research Organizations
  • 11.11. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Thermo Fisher Scientific, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Merck KGaA
    • 12.3.3. Bio-Rad Laboratories, Inc.
    • 12.3.4. Lonza Group AG
    • 12.3.5. F. Hoffmann-La Roche Ltd.
    • 12.3.6. Sartorius CellGenix GmbH
    • 12.3.7. Bio-Techne Corporation
    • 12.3.8. GenScript
    • 12.3.9. Miltenyi Biotec.
    • 12.3.10. Abcam PLC
    • 12.3.11. Sino Biological Inc.
    • 12.3.12. Cell Signaling Technology, Inc.
    • 12.3.13. ACROBiosystems
    • 12.3.14. Becton, Dickinson, and Company
    • 12.3.15. Creative Bioarray
    • 12.3.16. Applied Biological Materials (abm) Inc.
    • 12.3.17. GE Healthcare
    • 12.3.18. Meridian Bioscience Inc.
    • 12.3.19. Repligen Corporation
    • 12.3.20. Aviva Systems Biology Corporation (GenWay Biotech)
    • 12.3.21. Leadgene Biomedical, Inc.
    • 12.3.22. Boster Bio
    • 12.3.23. Prospec-Tany Technogene Ltd.
    • 12.3.24. Proteintech Group, Inc.
    • 12.3.25. AJINOMOTO CO.,INC
    • 12.3.26. STEMCELL Technologies
    • 12.3.27. Akron Biotech
    • 12.3.28. PeproTech Inc.

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations